Bacterially-produced small molecules demonstrate a wide range of structural and functional diversity. A new diketopiperazine, cyclo(D-trans-Hyp-L-Leu) (1), and five other known diketopiperazines (2-6), were isolated and purified from the fermented broth of a Kenyan bacterium Bacillus licheniformis LB 8C T . The structure of 1 was elucidated by a combination of extensive spectroscopic analyses, including 2D NMR and HR-MS, and the absolute configuration was determined by a combination of NOESY analysis and Marfey's method. The known compounds were identified as cyclo(D-cis-Hyp-L-Leu) (2), cyclo(D-cis-Hyp-L-Phe) (3), cyclo(D-Pro-L-Tyr) (4), cyclo-(D-Trp-L-Leu) (5), and cyclo(L-Tyr-Gly) (6) by comparison of their spectroscopic and physical data with reported values. Compounds 1-6 were tested for antifungal and antimicrobial properties.
Bacterially-produced small molecules exhibit a wide range of structural and functional diversity and have long been recognized as important sources for antibiotics and other medically useful drugs. However, the spread of drug resistance amongst bacteria and fungi, in particular human pathogens, makes the isolation and development of new and improved antimicrobials an essential goal of natural product chemistry. As a part of our ongoing search for new bioactive secondary metabolites, we investigated extracts obtained from cultures of a Bacillus licheniformis LB 8C T isolated from a soda lake in Kenya, which showed antimicrobial activity against Staphylococcus aureus at a concentration of 20 μg/mL. The chemical analysis of methanol extract resulted in the isolation of a new diketopiperazine (1) , and five other known diketopiperazines (2) (3) (4) (5) (6) (Figure 1 ). Diketopiperazines are cyclo-dipeptides obtained by the condensation of two α-amino acids and have been reported from various microorganisms [1] . Diketopiperazine moieties are also found in numerous natural products derived from fungi, bacteria, the plant kingdom, as well as mammals. These heterocyclic compounds display diverse pharmacological effects including antitumor [2] , antiviral [3] , antifungal [4] , and antibacterial activities [5] . We report herein the isolation and structure elucidation of compounds 1-6, as well as first investigations of their antifungal and antimicrobial properties.
Compound 1 was isolated as a white powder with a negative specific rotation value, [α] 25 D -137.5 (c 0.13, MeOH). Its molecular formula was determined to be C 11 H 18 N 2 O 3 from the [M + H] + peak at m/z 227.1407 (calcd. for C 11 H 19 N 2 O 3 , 227.1396) in the positiveion high resolution (HR)-ESI-MS. The IR spectrum of 1 showed a broad hydroxyl band at 3400 cm -1 and a carbonyl absorption band at 1661 cm -1 . The 1 H NMR spectrum (Table 1 ) of 1 showed signals for two methyl protons at  H 0.80 (d, J = 6.5 Hz) and 0.79 (d, J = 6.5 Hz). The 13 C NMR data (Table 1) of 1, which were assigned by HSQC and HMBC, displayed signals for two carbonyl resonances at  C 172.6 and 169.0. An analysis of the COSY, HSQC, and HMBC data obtained for 1 revealed the presence of two amino acids, leucine and 4-hydroxyproline. A 1 H resonance at  H 4.47, which corresponded to the carbon signal at  C 57.2 according to HSQC data, was typical for the α-position of an amino acid moiety. This resonance showed a series of COSY correlations for H-3/H-4/H-5 ( Figure 2 ), suggesting the presence of the hydroxyproline group. A 1 H resonance at  H 4.19 attached to the carbon resonance at  C 53.5, another typical α-proton of an amino acid residue, showed a series of COSY correlations for H-3/H-4/H-5/H-6 ( Figure 2 ), indicating the presence of the leucine group. HMBC correlations from these α-protons of two amino acid residues to two carbonyl carbon resonances at  C 172.6 and 169.0 indicated that compound 1 was a diketopiperazine composed of two amino acids, leucine and 4-hydroxyproline. The full NMR assignments of 1 were carried out by the analysis of the 1 H-1 H COSY, HSQC, and HMBC spectroscopic data ( Table 1) .
The 1 H and 13 C NMR data of 1 were very similar to those of 2, with apparently slight differences in the chemical shifts and coupling constants for H-3, H-4, and H-5 in 1 compared with the corresponding ones in 2, which indicated that compound 1 is an isomer of compound 2. The stereochemistry of 1 was determined by using a combination of NOESY analysis, degradative reaction, and derivatization. The relative configuration of the three stereogenic centers in 1 was established as 2R*, 4S*, and 2′S* by NOESY spectral analysis combined with molecular modeling (Figure 2 ). The absolute configuration of the leucine residue was determined by Marfey's method [6] . A small sample of 1 (0.3 mg) was hydrolyzed with 6 N HCl (1 mL) at 110°C for 15 h and derivatized with Marfey's reagent (N α -(2,4-dinitro-5-fluorophenyl)-Lalaninamide; L-FDAA). A comparison by LC-MS of the Marfey's derivative derived from 1 with Marfey's derivatives prepared from either D-or L-leucine showed that compound 1 contains L-leucine, which indicated the absolute configuration of the α-position of the leucine residue as 2′S. This analysis also determined 2R and 4S configurations based on the relative stereochemistry previously determined by NOESY experiment. Thus, the structure of 1 was established as a cyclic dipeptide, namely, cyclo(D-trans-Hyp-L-Leu).
The known compounds were identified as cyclo(D-cis-Hyp-L-Leu) (2) [7] , cyclo(D-cis-Hyp-L-Phe) (3) [7] , cyclo(D-Pro-L-Tyr) (4) [7] , cyclo-(D-Trp-L-Leu) (5) [8] , and cyclo(L-Tyr-Gly) (6) [9] , by comparison of their spectroscopic and physical data with reported values. Their absolute configurations were established using a combination of NOESY experiment and Marfey's method.
The isolated diketopiperazines 1-6 were tested for antifungal and antimicrobial properties in triplicate against standardized bacterial and yeast strains from the American Type Culture Collection [Gram-negative bacterium; Escherichia coli (ATCC 25922), Grampositive bacteria; Bacillus subtilis (ATCC 6633) and Staphylococcus aureus (BAA-2313); and yeasts; Saccharomyces cerevisiae (ATCC 9763) and Candida albicans (ATCC 10231)]. In this study, the minimum inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) values of compounds 1-6 were determined using broth-dilution techniques. Unfortunately none of the isolated compounds displayed antimicrobial activities below a concentration of 200 µg/mL.
Experimental
General experimental procedures: Optical rotations were obtained using a Jasco P-1010 polarimeter. UV spectra were recorded on an Amersham Biosciences Ultrospec 5300 Pro spectrophotometer, IR spectra on a Bruker Alpha-P spectrometer, and all NMR experiments on a Varian INOVA 600 NMR spectrometer. ESIMS spectra were obtained by LC/MS analysis, which was performed on an Agilent 1200 Series HPLC/6130 Series mass spectrometer. High resolution mass spectra were obtained on a Waters Micromass Q-Tof Ultima ESI-TOF mass spectrometer. All the compounds were purified on an Agilent 1100 series HPLC (Agilent Technologies) using a Phenomenex Luna phenyl-hexyl column (250 × 10 mm, 5 μm particle size), a Phenomenex Luna phenyl-hexyl column (250 × 21.2 mm, 10 μm particle size) and a Phenomenex Luna C 18 HPLC column (250 × 21.2 mm, 5 μm particle size).
Isolation and fermentation of bacterium LB 8C T :
The bacterium designated LB 8C T was isolated from a soda lake in Kenya. Soil samples were streaked on modified Horikoshi media (Horikoshi, 1991) containing 10% Na 2 CO 3 solution and incubated at 55C. The isolate was re-streaked on agar plates, and the plates incubated at 55°C for 12 h. Strain LB 8C T was identified based on morphology and 16S sequencing, and plated on modified Horikoshi media until clean isolates were obtained. Pure colonies were maintained as glycerol stocks (40%) at -80ºC. Strain LB 8C T was identified and prioritized for analysis on the basis of its antimicrobial activity. A region of the 16S rDNA gene was amplified for phylogenetic analysis with general primers 27F and 1492R using standard DNA extraction and PCR protocols. A nucleotide BLAST search of the partial 16S rRNA sequence for LB 8C T revealed that it had a 95% identity match with the partial 16S rRNA sequence for B. licheniformis with the GenBank accession number DQ112220.1. The partial sequence of the 16S ribosomal RNA gene of LB 8C T was deposited under GenBank accession number: EF113327.1.
Extraction and isolation:
The methanol extract (619.5 mg) of the plates of LB 8C T was separated by preparative HPLC (phenylhexyl, Phenomenex, Luna, 250 × 21.2 mm, 5 μm) using a flow rate of 10 mL/min and gradient elution from 5% MeCN (+0.1% formic acid) to 50% MeCN (+0.1% formic acid) in 30 min and from 50% MeCN (+0.1% formic acid) to 100% MeCN (+0.1% formic acid) in the next 5 min to give 35 fractions. Fraction 14 was further separated by preparative HPLC (phenyl-hexyl, Phenomenex, Luna, 250 × 21.2 mm, 5 μm) using a flow rate of 10 mL/min and isocratic elution with 13% MeCN (+0.1% formic acid) in 20 min and gradient elution from 13% MeCN (+0.1% formic acid) to 50% MeCN (+0.1% formic acid) in the next 10 min and from 50% MeCN (+0.1% formic acid) to 100% MeCN (+0.1% formic acid) in the next 10 min to yield 40 sub-fractions (Fr. 14-1 -Fr. 14-40). From sub-fraction 14-11, compound 6 (t R 22.3 min, 0.5 mg) was obtained by HPLC employing a phenyl-hexyl column (Phenomenex, Luna, 250 × 10 mm, 5 μm) using isocratic elution with 11% MeCN (+0.1% formic acid) and a flow rate of 2 mL/min. Compound 4 (t R 21.2 min, 0.3 mg) was purified by HPLC employing a phenyl-hexyl column (Phenomenex, Luna, 250 × 10 mm, 5 μm; 2 mL/min) using isocratic elution with 12% MeCN (+0.1% formic acid) from sub-fraction 14-13. Fraction 16 was purified by a phenyl-hexyl HPLC column (Phenomenex, Luna, 250 × 10 mm, 5 μm; 2 mL/min) using isocratic elution with 14% MeCN (+0.1% formic acid) to yield compounds 1 (t R 20.3 min, 1.2 mg), 2 (t R 19.7 min, 1.2 mg), and 5 (t R 21.6 min, 0.5 mg). Fraction 17 was separated by a phenyl-hexyl HPLC column (Phenomenex, Luna, 250 × 10 mm, 5 μm; 2 mL/min) using isocratic elution with 13% using isocratic elution to afford compound 3 (t R 29.3 min, 1.0 mg). ( 
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Marfey's analysis of 1:
A small sample of 1 (0.3 mg) was hydrolyzed with 6N HCl (1 mL) at 110°C for 15 h. The reaction was allowed to cool to room temperature, and dried in vacuo. A solution of Marfey's reagent (20 μL, 10 mg/mL in acetone) was added, followed by 1 N aqueous NaHCO 3 (100 μL). The reaction was heated to 80°C for 10 min, cooled to room temperature, and acidified with 2 N HCl (50 μL). The reaction mixture was filtered and analyzed by LC-MS using the following gradient; 0-30 min, linear gradient from 10-70% CH 3 CN/H 2 O + 0.1% formic acid; 30-40 min, linear gradient from 70-100% CH 3 CN/H 2 O + 0.1% formic acid. Standards were prepared from the appropriate authentic D-or L-amino acids (0.2 mg) by derivatizing them with Marfey's reagent using the above procedure. The retention times for Marfey's derivatives were as follows: derivative prepared from 1, 22.0 min, from authentic L-leucine, 22.0 min, and from authentic D-leucine, 23.9 min. The sample prepared from 1 was also co-injected with standards to confirm its assignment, which proved that compound 1 has L-leucine. The other compounds were analyzed using the same procedure.
Antifungal and antimicrobial assay: Each isolated compound was tested for antifungal and antimicrobial activity in triplicate against standardized bacterial and yeast strains from the American Type Culture Collection [Escherichia coli (ATCC 25922), Bacillus subtilis (ATCC 6633), Staphylococcus aureus (BAA-2313), Saccharomyces cerevisiae (ATCC 9763), and Candida albicans (ATCC 10231)]. MIC (minimum inhibitory concentration) and MFC (minimum fungicidal concentration) values for E. coli, B. subtilis, S. aureus, S. cerevisiae and C. albicans were determined using broth-dilution techniques. E. coli, B. subtilis, and S. aureus were grown in LB-Miller broth (5 mL), and S. cerevisiae and C. albicans in YP broth (5 mL) at 30°C overnight to an OD 600nm > 0.9. The cultures were diluted 1:100 with LB-Miller broth to an approximate OD 600nm of 0.05, and 100 μL aliquots of diluted culture were added to a series of wells in a 96-well plate. A 0.1 mg/100 μL DMSO stock solution of each compound was used for testing (titration from 1 μL up to 12 μL of substrate solution, in 1 μL steps). Streptomycin sulfate and amphotericin B were used as positive controls. After incubation at 30°C for 12 h the OD 600nm was measured using a SpectraMax M5 Multi-Mode Microplate Reader. Cultures in wells showing no growth were plated on agar plates (LB for E. coli, B. subtilis, and S. aureus assays, and YP for S. cerevisiae and C. albicans assays) and incubated at 30°C for 48 h to verify loss of viability. MIC 50 values were calculated using XLfit 4.2 software. MIC was determined as the lowest concentration that caused complete growth inhibition (fungistatic) while the MFC was the lowest concentration that killed 99.9% of the cells (fungicidal).
Supplementary data: NMR data of compound 1 are available in electronic form on the publisher's website.
